• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Infection and immunity >Evaluation of a Truncated Recombinant Flagellin Subunit Vaccine against Campylobacter jejuni
【24h】

Evaluation of a Truncated Recombinant Flagellin Subunit Vaccine against Campylobacter jejuni

机译：空肠弯曲菌截短重组鞭毛蛋白亚单位疫苗的评价

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A recombinant protein comprising the maltose-binding protein (MBP) of Escherichia coli fused to amino acids 5 to 337 of the FlaA flagellin of Campylobacter coli VC167 was evaluated for immunogenicity and protective efficacy against challenge by a heterologous strain of campylobacter, Campylobacter jejuni81-176, in two murine models. The sequence of the flaA gene of strain 81-176 revealed a predicted protein which was 98.1% similar to that of VC167 FlaA over the region expressed in the fusion protein. Mice were immunized intranasally with two doses of 3 to 50 μg of MBP-FlaA, given 8 days apart, with or without 5 μg of the mutantE. coli heat-labile enterotoxin (LTR192G) as a mucosal adjuvant. The full range of MBP-FlaA doses were effective in eliciting antigen-specific serum immunoglobulin G (IgG) responses, and these responses were enhanced by adjuvant use, except in the highest dosing group. Stimulation of FlaA-specific intestinal secretory IgA (sIgA) responses required immunization with higher doses of MBP-FlaA (≥25 μg) or coadministration of lower doses with the adjuvant. When vaccinated mice were challenged intranasally 26 days after immunization, the best protection was seen in animals given 50 μg of MBP-FlaA plus LTR192G. The protective efficacies of this dose against disease symptoms and intestinal colonization were 81.1 and 84%, respectively. When mice which had been immunized with 50 μg of MBP-FlaA plus LTR192G intranasally were challenged orally with 8 × 1010, 8 × 109, or 8 × 108 cells of strain 81-176, the protective efficacies against intestinal colonization at 7 days postinfection were 71.4, 71.4, and 100%, respectively.
机译：评价了包含与大肠杆菌弯曲菌FlaA鞭毛蛋白第5至337位氨基酸融合的大肠杆菌的麦芽糖结合蛋白（MBP）的重组蛋白的免疫原性和保护性两种鼠模型对弯曲杆菌空肠弯曲杆菌 Campylobacter jejuni 81-176的抗药性的功效。菌株81-176的 flaA 基因的序列显示，在融合蛋白表达的区域中，预测的蛋白与VC167 FlaA的预测蛋白相似，为98.1％。小鼠每隔8天鼻内给予2剂3至50μgMBP-FlaA剂量的鼻内免疫，有或没有5μg突变体em。大肠杆菌热不稳定肠毒素（LT R192G ）作为粘膜佐剂。 MBP-FlaA的整个剂量范围均可有效引发抗原特异性血清免疫球蛋白G（IgG）应答，除最高剂量组外，这些应答可通过佐剂使用得到增强。刺激FlaA特异性肠道分泌型IgA（sIgA）反应需要使用更高剂量的MBP-FlaA（≥25μg）进行免疫接种，或者与更低剂量的佐剂共同给药。免疫后26天经鼻内接种疫苗的小鼠，在给予50μgMBP-FlaA和LT R192G 的动物中获得了最好的保护。该剂量对疾病症状和肠道菌落的保护作用分别为81.1和84％。鼻内用50μgMBP-FlaA和LT R192G 免疫的小鼠口服8×10 10 攻击，8×10 9 或8×10 8 菌株81-176，在感染后7天对肠道菌落的保护作用分别为71.4、71.4和100％。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号